Loading
Oral kinase inhibitors, CDK4/6 inhibitors and hormonal agents interact with proton pump inhibitors, anticoagulants, statins and antiarrhythmics, and are increasingly prescribed to older patients taking all of them. A mandatory oncology pharmacist review at initiation, dose change and refill, with a structured monitoring plan, would catch these interactions systematically.
Oral kinase inhibitors, CDK4/6 inhibitors, and hormonal agents have clinically significant interactions with proton pump inhibitors, anticoagulants, statins, and antiarrhythmics, and are increasingly prescribed to older multimorbid patients. Studies find potential interactions in a large proportion of such patients. A mandatory oncology pharmacist review at initiation and dose change, with a structured monitoring plan, would catch these systematically.
Shares Palbociclib, CDK4/6 inhibitors, Small-molecule kinase inhibitors.
Shares Palbociclib, CDK4/6 inhibitors, Small-molecule kinase inhibitors.
Shares Older and multimorbid patients are excluded and undertreated, Toxicity and quality of life are undervalued.
Shares Palbociclib, CDK4/6 inhibitors, Small-molecule kinase inhibitors.
Shares Older and multimorbid patients are excluded and undertreated, Toxicity and quality of life are undervalued.
Shares Palbociclib, CDK4/6 inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/